Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies
Authors:
- 1 June 2017
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 261, 1-11
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Arterial Klotho Expression and FGF23 Effects on Vascular Calcification and FunctionPLOS ONE, 2013
- Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the communityKidney International, 2013
- Update on fibroblast growth factor 23 in chronic kidney diseaseKidney International, 2012
- Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living IndividualsJACC, 2012
- Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysisBone, 2012
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patientsNephrology Dialysis Transplantation, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986